Pharming Group N.V. current report, Q3 FY2026

Full document

Pharming Group N.V. — Form 6-K Summary

Business Context and Reporting Period

Pharming Group N.V., a Netherlands-based biotechnology company focused on rare immune and genetic diseases, filed this Form 6-K for September 2026. The filing furnishes a September 25, 2026 press release announcing U.S. FDA acceptance and Priority Review of a supplemental New Drug Application (sNDA) for lower doses of Joenja® (leniolisib).

Key Financial and Operating Metrics

  • The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, working-capital, or other financial metrics.
  • Joenja is an oral PI3Kδ inhibitor approved in multiple markets for APDS, including U.S. approval for adults and pediatric patients aged 12 years and older and, following a September 2026 expansion, children aged 4 to 11 years weighing at least 27 kg.
  • The pending U.S. sNDA seeks approval for children aged 4 years and older weighing between 13 kg and 27 kg.

Material Changes Versus the Prior Comparable Period

  • The FDA accepted the sNDA and granted it Priority Review, expanding the potential U.S. pediatric population for Joenja if approved.
  • The announcement follows the recent U.S. approval for children aged 4 to 11 years who weigh at least 27 kg.
  • The filing does not provide a prior-period financial comparison.

Guidance, Outlook, Risks, and Unusual Items

  • The FDA assigned a Prescription Drug User Fee Act target action date of January 30, 2027. This is a regulatory target, not an approval decision.
  • The application is supported by a multinational, open-label, single-arm Phase III study in children aged 4 to 11 years. Over 12 weeks, the study reported reduced lymphadenopathy and increased naive B cells, together indicating correction of the underlying immune defect, according to the release.
  • Management stated that the Priority Review brings Pharming closer to potentially treating smaller children with APDS who are currently ineligible for Joenja.
  • Approval, timing, commercial prospects, clinical development, costs, regulatory outcomes, and future cash-resource requirements remain subject to risks and uncertainties.
  • The release states that leniolisib is under regulatory review in several other countries and is being evaluated in two Phase II trials for primary immunodeficiencies with immune dysregulation. Safety and efficacy for those conditions beyond APDS have not been established.
  • The release includes customary forward-looking-statement risk language and refers investors to Pharming’s 2025 Annual Report and Form 20-F for the year ended December 31, 2025.
  • The announcement qualifies as information that may constitute inside information under the EU Market Abuse Regulation.

Important Facts for Investors to Verify

  • Whether the FDA approves the lower-dose sNDA by, or before or after, the January 30, 2027 PDUFA target date.
  • The final approved patient age and weight ranges, dosing regimen, labeling, and any post-marketing requirements.
  • The strength, duration, and safety profile of the pediatric clinical data supporting the application.
  • The commercial impact of expanding Joenja access to lower-weight children, including reimbursement and patient-identification considerations.
  • Pharming’s current revenue, cash position, liquidity runway, debt, operating expenses, and any updated financial guidance, none of which are provided in this filing.